Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Eli Lilly has launched its diabetes and weight-loss drug Mounjaro in India after receiving regulatory approval. The launch ...

ASX health stocks broke their losing streak this week, while it was a big week for Nanosonics, Neurizon and Sigma.

A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...

Second Front Systems (2F), a public-benefit software company focused on facilitating the delivery of mission-critical software solutions, today announced the appointment of Drew Hoffman as President ...

MUCH has been said about the backlog of 2.4 million cases in the judicial system ... where couples had dual nationality. Since then, judges have decided each case de novo. In some cases, courts ...

Monica Novo of Douglas Elliman. Simmons purchased two under-construction ... feet of Widell & Boschetti-designed living space armed with a Savant home-automation system. More from Robb Report This $59 ...

Rigel Therapeutics expands oncology portfolio with REZLIDHIA & GAVRETO, sees promising R289 results. Click here to read my ...

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been ... The result from the SUMMIT study helps Lilly close the gap with Novo Nordisk, whose GLP-1 agonist semaglutide is already approved ...